This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (23)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Ophthalmology  • Ophthalmological Disorders  • Pediatric Ophthalmology  • Ophthalmological Disorders, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Berna Atik, MD, MPH; Ton Ton Kim Thanh, MD; Vu Quoc Luong, MD; Stephane Lagree, PhD; Deborah Dean, MD, MPH

JAMA. 2006;296:1488-1497.

Context  The World Health Organization developed the SAFE strategy (Surgery for trichiasis; Antibiotics for Chlamydia trachomatis infection; Facial cleanliness; and Environmental improvement) to eliminate blinding trachoma globally by the year 2020. Despite a number of studies using various intervals of treatment for different prevalence rates, there has been a lack of sufficient follow-up beyond the final treatment point to determine rates of recurrence of disease and infection and the risk factors that may contribute to each.

Objective  To evaluate the impact of 2 annual targeted azithromycin treatments on active trachoma and C trachomatis infection rates over 3 years in Vietnam.

Design, Setting, and Participants  Three communes were randomly selected for a longitudinal study in Vietnam from November 2000 through November 2003. Individuals (n = 3186) were graded for trachoma followed by conjunctival sampling to detect chlamydiae by commercial polymerase chain reaction. Grading and chlamydial detection were repeated every 6 months for 3 years.

Intervention  Azithromycin was given to children aged 5 through 15 years with active trachoma and their household members in SAFE and SA communes at baseline and 12 months; these communes were compared with the S-only control commune that did not receive azithromycin targeted treatment.

Main Outcome Measures  Prevalence and incidence of active trachoma and C trachomatis infection in all communes at baseline, 6, 12, 18, 24, and 36 months. Subgroup analysis evaluated new infection, continuing infection, and reinfection at 6, 12, 18, 24, and 36 months and risk factors for each.

Results  Reinfection rates increased significantly between 12 and 36 months for SAFE (from 1.6 to 29.3 per 1000; P<.001) and SA (5.1 to 25.3 per 1000; P = .002) communes but not for the S-only commune (13.4 to 6.7 per 1000; P = .55) after 24 months. Compared with the S-only commune, mixed-effects and generalized estimating equations (GEE) logistic models showed that reinfection risk was significantly higher for SAFE (odds ratio [OR], 4.1; 95% confidence interval [CI], 1.5-9.8; P = .005) and SA (OR, 4.2; 95% CI, 1.1-17.3; P = .04) communes at 36 months.

Conclusions  Increasing reinfection rates suggest that treatment may interrupt the duration of infection required for developing immunity, increasing the number of individuals susceptible to reinfection and adversely affecting disease prevalence over time. Additional research is needed to determine optimal trachoma control strategies, including evaluation of the "F" and "E" components.

Trial Registration  www.actr.org.au Identifier: 12606000360516

Author Affiliations: Children's Hospital Oakland Research Institute, Oakland, Calif (Drs Atik and Dean); National Institute of Ophthalmology, Hanoi, Vietnam (Drs Thanh and Luong); International Trachoma Initiative, Hanoi, Vietnam (Dr Lagree); and Department of Medicine, University of California at San Francisco School of Medicine (Dr Dean).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Targeted Treatment of Active Trachoma
David Mabey, Robin Bailey, Anthony Solomon, Matthew Burton, Clare Gilbert, Allen Foster, Thomas Lietman, and Sheila West
JAMA. 2007;297(6):588.
EXTRACT | FULL TEXT  

Targeted Treatment of Active Trachoma
Chandler R. Dawson and Julius Schachter
JAMA. 2007;297(6):588-589.
EXTRACT | FULL TEXT  

Targeted Treatment of Active Trachoma—Reply
Deborah Dean, Berna Atik, Ton Thi Kim Thanh, Vu Quoc Luong, and Stephan Lagree
JAMA. 2007;297(6):589-590.
EXTRACT | FULL TEXT  

RELATED ARTICLE

The Return of Trachoma in Partially Treated Communities
Jon L. Yang and Thomas M. Lietman
Arch Ophthalmol. 2007;125(7):989-991.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of Mass Distribution of Azithromycin for Trachoma Control on Overall Mortality in Ethiopian Children: A Randomized Trial
Porco et al.
JAMA 2009;302:962-968.
ABSTRACT | FULL TEXT  

Age, Sex, and Cohort Effects in a Longitudinal Study of Trachomatous Scarring
Wolle et al.
IOVS 2009;50:592-596.
ABSTRACT | FULL TEXT  

Caution: chlamydia surveillance data ahead
Low
Sex. Transm. Infect. 2008;84:80-81.
FULL TEXT  

Epidemiology of chlamydial infection: are we losing ground?
Rekart and Brunham
Sex. Transm. Infect. 2008;84:87-91.
ABSTRACT | FULL TEXT  

Comparison of Annual and Biannual Mass Antibiotic Administration for Elimination of Infectious Trachoma
Melese et al.
JAMA 2008;299:778-784.
ABSTRACT | FULL TEXT  

The Return of Trachoma in Partially Treated Communities
Yang and Lietman
Arch Ophthalmol 2007;125:989-991.
FULL TEXT  

Trachoma and Ocular Chlamydia trachomatis Were Not Eliminated Three Years after Two Rounds of Mass Treatment in a Trachoma Hyperendemic Village
West et al.
IOVS 2007;48:1492-1497.
ABSTRACT | FULL TEXT  

Targeted Treatment of Active Trachoma
Mabey et al.
JAMA 2007;297:588-588.
FULL TEXT  

Targeted Treatment of Active Trachoma
Dawson and Schachter
JAMA 2007;297:588-589.
FULL TEXT  

What's new in the other general journals
Tonks
BMJ 2006;333:744-745.
FULL TEXT